Asokan Mangaiarkarasi, Sachidanandam Vijaya, Satish Kadappa Shivappa, Ranga Udaykumar
HIV-AIDS Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, 560 064 India.
Microbiology and Cell Biology Department, Indian Institute of Science, Bangalore, 560 012 India.
Virusdisease. 2014;25(3):302-13. doi: 10.1007/s13337-014-0218-8. Epub 2014 May 21.
To explain a stable clinical outcome observed in a previous pilot clinical trial using a polyherbal formulation (PHF) for HIV-AIDS, we, in the present study, evaluated the T cell functions from fresh and stored blood samples. In three clinical groups-the anti-retroviral therapy, PHF and control arms-we compared the circulating levels of lipopolysaccharide, LPS-binding protein, soluble CD14, aspartate transaminase (AST) and alanine transaminase (ALT). Additionally, we evaluated the expression of T cell markers and gag-specific immune responses. The PHF treatment significantly reduced the levels of sCD14, AST and ALT. In a cross-sectional analysis at 30 months post-treatment, in comparison to the control group, the PHF arm showed significantly low per-cell expression of PD1, CD95 and HLA-DR. The PHF treatment appears to have attenuated general immune activation and hepatic inflammation in the study participants. Targeting the mediators of immune activation must be pursued as a useful strategy for HIV-AIDS management.
为了解释在先前一项使用多草药配方（PHF）治疗艾滋病的试点临床试验中观察到的稳定临床结果，在本研究中，我们评估了新鲜和储存血样中的T细胞功能。在三个临床组（抗逆转录病毒治疗组、PHF组和对照组）中，我们比较了脂多糖、LPS结合蛋白、可溶性CD14、天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）的循环水平。此外，我们评估了T细胞标志物的表达和gag特异性免疫反应。PHF治疗显著降低了sCD14、AST和ALT的水平。在治疗后30个月的横断面分析中，与对照组相比，PHF组的PD1、CD95和HLA-DR的单细胞表达显著降低。PHF治疗似乎减轻了研究参与者的全身免疫激活和肝脏炎症。针对免疫激活介质进行干预必须作为艾滋病管理的一种有效策略来推行。
